Dr. Jabbour Discusses Blinatumomab in ALL

Elias Jabbour, MD
Published: Wednesday, Aug 01, 2018



Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).

Blinatumomab has shown a significant impact on the treatment landscape of ALL in the last few years. In July 2017, the FDA granted a full approval to blinatumomab as a treatment for adults and children with relapsed/refractory B-cell precursor ALL, regardless of Philadelphia chromosome status. In March 2018, the FDA granted an accelerated approval to blinatumomab for the treatment of adult and pediatric patients with B-cell precursor ALL who are in remission but still have minimal residual disease (MRD).

Jabbour says that among patients with MRD-positive ALL in hematologic complete remission (CR), the response rate to blinatumomab was 80%. An improvement in both progression-free survival and overall survival has been observed with these patients who have responded to blinatumomab. These data came from the BLAST study, which was a single-arm trial of up to 4 cycles of blinatumomab for the treatment of patients with B-cell precursor ALL in CR or CR with partial platelet recovery and MRD >0.1%.


Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).

Blinatumomab has shown a significant impact on the treatment landscape of ALL in the last few years. In July 2017, the FDA granted a full approval to blinatumomab as a treatment for adults and children with relapsed/refractory B-cell precursor ALL, regardless of Philadelphia chromosome status. In March 2018, the FDA granted an accelerated approval to blinatumomab for the treatment of adult and pediatric patients with B-cell precursor ALL who are in remission but still have minimal residual disease (MRD).

Jabbour says that among patients with MRD-positive ALL in hematologic complete remission (CR), the response rate to blinatumomab was 80%. An improvement in both progression-free survival and overall survival has been observed with these patients who have responded to blinatumomab. These data came from the BLAST study, which was a single-arm trial of up to 4 cycles of blinatumomab for the treatment of patients with B-cell precursor ALL in CR or CR with partial platelet recovery and MRD >0.1%.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x